Delft-based neurotechnology startup STIL has announced the acquisition of €2 million in growth capital, marking a significant milestone in its quest to enhance the lives of individuals with tremor disorders. This strategic funding will support the company in expanding its team and solidifying clinical partnerships, as well as accelerating its efforts to enter international markets. With tremor disorders affecting a broad population globally, STIL endeavors to offer a practical solution that alleviates the challenges associated with these conditions.
Before the latest funding, STIL had already established a solid presence with significant funding rounds, including €3.6M from notable investors. The company’s innovative approach to tremor treatment, utilizing non-invasive and wearable technology, has garnered attention and support over the last few years. As STIL continues to grow, its commitment to advancing medical solutions remains steadfast, reinforcing its position in the European neurotechnology landscape.
What Issues Are STIL Addressing?
Tremor disorders, including those associated with Parkinson’s Disease and essential tremor, create involuntary limb shaking, severely impacting daily functions such as eating and drinking. Despite their prevalence, these conditions lack a definitive cure, with existing treatments often proving ineffective or invasive. Addressing these challenges, STIL seeks to provide a novel remedy that mitigates the debilitating impacts of tremors.
How Is STIL Revolutionizing Treatment?
STIL has engineered an anti-tremor orthosis, a CE-marked medical device designed to suppress tremors while preserving voluntary movements. With this innovative solution, STIL targets a critical gap in the treatment of tremor disorders. The orthosis, aimed at reducing forearm tremors by over 80%, facilitates the accomplishment of everyday tasks, ultimately empowering individuals by restoring their autonomy. STIL’s founders, IJsbrand de Lange and Nicola Pambakian, emphasize the orthosis’s immediate symptom relief and ease of use.
The orthosis operates through advanced dampers that differentiate between involuntary tremors and voluntary muscle actions, offering a new level of freedom for users. In contrast to invasive surgical options and drug dependence, STIL Orthosis provides a wearable alternative, leveraging proprietary algorithms to modulate specific muscle activities effectively. This neuromodulation technique reflects STIL’s commitment to less intrusive healthcare solutions.
STIL’s expansion within Europe is well underway, with established distribution partnerships in countries such as the Netherlands, Germany, Belgium, and Italy. By the end of 2024, the startup had distributed hundreds of devices throughout these regions, showcasing its growth and market acceptance. Their robust clinical approach and expanding international reach signify STIL’s role in redefining tremor management.
The recent €2M investment strengthens STIL’s trajectory, providing essential resources for development and market penetration. By focusing on non-invasive, effective solutions, STIL aligns with current healthcare trends emphasizing patient-centered innovative treatments. This injection of capital also highlights investor confidence in STIL’s strategic direction and market potential.
Moving forward, STIL stands at the forefront of a promising segment within the healthcare device sector. With a focus on accessibility and functionality, STIL’s orthosis exemplifies the ongoing shift towards technology-driven solutions. As adoption widens, the potential impact of enhancing life quality for individuals with tremor disorders solidifies STIL’s reputation in the medical technology landscape.
